May 16, 2022 – We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB). This new regimen represents a long-awaited breakthrough, offering a shorter alternative to the six-to-nine-month treatment in use since the 1980s. That the Department of Health and Mental Hygiene is moving forward to make this regimen available to patients will make treatment more tolerable for people living with TB. As TB survivor and activist Kate O’Brien of We Are TB and co-chair of the TB Roundtable put it, “TB treatment can be such a miserable experience, with all sorts of side effects and logistical complications. Shorter regimens offer patients welcome relief and I’m thrilled to see important government investments delivering better cures for TB.”

On 4 May 2022, Treatment Action Group (TAG) and the Coalition of Women Living with HIV and AIDS (COWLHA) hosted a webinar on how community-led monitoring can be used to generate evidence for advocacy to improve the availability, accessibility, acceptability, and quality of TB screening and diagnostic services.

Treatment Action Group and the Coalition of Women Living with HIV and AIDS (COWLHA) will host a webinar on 4 May 2022 explaining how community-led monitoring can be used to generate evidence for advocacy to improve the availability, accessibility, acceptability, and quality of TB screening and diagnostic services. 

A tool, developed by the Coalition of Women Living with HIV and AIDS in partnership with Treatment Action Group, designed to equip communities to use community-lead monitoring to better understand the TB screening and diagnostic services, and to translate findings into evidence-based advocacy.

The #RightToPreventTB campaign focuses attention on the urgent need to scale-up TB preventive treatment as a matter of human rights.

Treatment Action Group (TAG) released an overview of TB data reported at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022. A summary of major findings and TAG’s take on them are available here.

A brief, released by Treatment Action Group, outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'